Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2

[1]  A. Gordon,et al.  Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants , 2022, Cell.

[2]  Xuping Xie,et al.  Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster , 2022, Nature Medicine.

[3]  M. Kiso,et al.  Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB , 2022, The Lancet Infectious Diseases.

[4]  N. Kitchin,et al.  Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine , 2022, bioRxiv.

[5]  Xuping Xie,et al.  Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine , 2022, Cell Reports.

[6]  Sarah A. Meyer,et al.  Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[7]  A. Ershov,et al.  Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021) , 2022, Vaccines.

[8]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[9]  S. Hoehl,et al.  Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes , 2022, Science Immunology.

[10]  J. Wakefield,et al.  Estimating global and country-specific excess mortality during the Covid-19 pandemic , 2022, The Annals of Applied Statistics.

[11]  N. Garrett,et al.  Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa , 2022, The New England journal of medicine.

[12]  A. Fomsgaard,et al.  Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine , 2022, JAMA network open.

[13]  Keda Chen,et al.  Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants , 2022, Frontiers in Immunology.

[14]  P. Dormitzer,et al.  BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants , 2022, npj Vaccines.

[15]  P. Dormitzer,et al.  BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants , 2022, NPJ vaccines.

[16]  O. Tsang,et al.  Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines , 2022, eBioMedicine.

[17]  Jieliang Chen,et al.  Omicron XE emerges as SARS-CoV-2 keeps evolving , 2022, The Innovation.

[18]  William F. Fadel,et al.  Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[19]  Phanikanth Jogam,et al.  Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms , 2022, Cells.

[20]  K. Swanson,et al.  Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine , 2022, Nature Communications.

[21]  J. L. Bernal,et al.  COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England , 2022, The Lancet Infectious Diseases.

[22]  M. Pai,et al.  It is not too late to achieve global covid-19 vaccine equity , 2022, BMJ.

[23]  M. García-Fiñana,et al.  Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2 , 2022, BMC Infectious Diseases.

[24]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.

[25]  H. Jacquier,et al.  Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments , 2022, Annals of Internal Medicine.

[26]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[27]  Sijia Chen,et al.  Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies , 2022, Vaccines.

[28]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[29]  A. Lanzavecchia,et al.  Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients , 2022, PloS one.

[30]  H. Schuitemaker,et al.  Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S , 2022, The New England journal of medicine.

[31]  P. Austin,et al.  Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario , 2022, Nature Microbiology.

[32]  A. Apisarnthanarak,et al.  Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study , 2022, Emerging microbes & infections.

[33]  M. Koopmans,et al.  Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients , 2022, Science Immunology.

[34]  G. Narasimhan,et al.  Changes in the receptor-binding interface may cause immune evasion by the SARS-CoV-2 delta variant b.1.617.2 , 2022, Biophysical Journal.

[35]  H. Wei,et al.  Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera , 2022, Viruses.

[36]  M. Suthar,et al.  Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants , 2022, medRxiv.

[37]  Siang Li Chua,et al.  Comparison of the clinical features, viral shedding and immune response in vaccine breakthrough infection by the Omicron and Delta variants , 2022, SSRN Electronic Journal.

[38]  J. Mascola,et al.  SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination , 2022, The New England journal of medicine.

[39]  V. Gushchin,et al.  Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals , 2022, medRxiv.

[40]  K. Dhama,et al.  Emergence of Omicron third lineage BA.3 and its importance , 2022, Journal of medical virology.

[41]  N. Andrews,et al.  Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England , 2022, Nature Medicine.

[42]  Nimisha Ghosh,et al.  A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein , 2022, International Immunopharmacology.

[43]  E. Albert,et al.  Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents , 2021, Scientific Reports.

[44]  F. Sun,et al.  Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis , 2021, BMC Medicine.

[45]  L. Bekker,et al.  Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.

[46]  Shirin Djalalinia,et al.  Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies , 2021, Vaccines.

[47]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[48]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[49]  Heidi Ledford,et al.  How COVID vaccines shaped 2021 in eight powerful charts , 2021, Nature.

[50]  Learn‐Han Lee,et al.  COVID-19: Gastrointestinal Manifestations and Complications , 2021, Progress In Microbes & Molecular Biology.

[51]  N. Rezaei,et al.  COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts , 2021, Journal of medical virology.

[52]  Ikbel Hadj Hassine.  Covid‐19 vaccines and variants of concern: A review , 2021, Reviews in medical virology.

[53]  V. Letchumanan,et al.  Insights into COVID-19 Delta variant (B.1.617.2) , 2021, Progress In Microbes & Molecular Biology.

[54]  M. Coccia.  Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis , 2021, Environmental Research.

[55]  A. Sheikh,et al.  BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant , 2021, The New England journal of medicine.

[56]  M. Hernán,et al.  Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents , 2021, The New England journal of medicine.

[57]  I. Diamond,et al.  Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.

[58]  Elaheh Entezar-Almahdi,et al.  Drug-based therapeutic strategies for COVID-19-infected patients and their challenges , 2021, Future microbiology.

[59]  A. Huppert,et al.  BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals , 2021, Journal of Clinical Epidemiology.

[60]  A. Ryo,et al.  Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay , 2021, Journal of Infection and Chemotherapy.

[61]  Meei-Li W Huang,et al.  Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants , 2021, medRxiv.

[62]  K. Natarajan,et al.  Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[63]  A. Dehshahri,et al.  A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines , 2021, International Immunopharmacology.

[64]  O. Dyer.  Covid-19: Unvaccinated face 11 times risk of death from delta variant, CDC data show , 2021, BMJ.

[65]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.

[66]  Vaccine Ontology.  Moderna COVID-19 vaccine , 2021, Definitions.

[67]  Xing Wu,et al.  Impact of the Delta variant on vaccine efficacy and response strategies , 2021, Expert review of vaccines.

[68]  S. Bhatt,et al.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.

[69]  D. Parums.  Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[70]  Afsaneh Vazin,et al.  Micronutrients Supplementation in Pregnant Women during COVID-19 Pandemy: Pros and Cons , 2021 .

[71]  A. Iwasaki,et al.  COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants , 2021, Cell.

[72]  H. L. Braz,et al.  Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India) , 2021, Journal of Virus Eradication.

[73]  Wildo Navegantes de Araújo,et al.  Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study , 2021, BMJ.

[74]  Elisabeth Mahase.  Covid-19: How many variants are there, and what do we know about them? , 2021, BMJ.

[75]  C. del Rio,et al.  Confronting the Delta Variant of SARS-CoV-2, Summer 2021. , 2021, JAMA.

[76]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[77]  C. Lorson,et al.  Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses , 2021, Journal of Autoimmunity.

[78]  R. Condos,et al.  CT of Postacute Lung Complications of COVID-19 , 2021, Radiology.

[79]  S. Ciesek,et al.  Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q , 2021, medRxiv.

[80]  Y. Liu,et al.  The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus , 2021, Journal of travel medicine.

[81]  T. Fiolet,et al.  Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.

[82]  Wildo Navegantes de Araújo,et al.  Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study , 2021, The Lancet Regional Health - Americas.

[83]  M. Mulligan,et al.  Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants , 2021, bioRxiv.

[84]  H. Schuitemaker,et al.  Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination , 2021, The New England journal of medicine.

[85]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[86]  S. Panda,et al.  Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin , 2021, Journal of travel medicine.

[87]  Mehrdad Mohammadi,et al.  The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines , 2021, The Brazilian Journal of Infectious Diseases.

[88]  S. Mohammadi-Samani,et al.  The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate COVID-19: A personal experience from an attending pharmacist and his resident. , 2021, Acta bio-medica : Atenei Parmensis.

[89]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[90]  P. Meredith,et al.  The SARS-CoV-2 B.1.1.7 variant and increased clinical severity—the jury is out , 2021, The Lancet Infectious Diseases.

[91]  G. Sourvinos,et al.  Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers , 2021, Infectious diseases.

[92]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[93]  N. Ghiasi,et al.  Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion , 2021, Immunopathologia Persa.

[94]  Wenbo Xu,et al.  COVID-19 Cases from the First Local Outbreak of the SARS-CoV-2 B.1.1.7 Variant in China May Present More Serious Clinical Features: A Prospective, Comparative Cohort Study , 2021, medRxiv.

[95]  D. Moodley,et al.  Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, The New England journal of medicine.

[96]  M. Cámara,et al.  A Review of the Role of Micronutrients and Bioactive Compounds on Immune System Supporting to Fight against the COVID-19 Disease , 2021, Foods.

[97]  A. Nagy,et al.  An overview of current COVID-19 vaccine platforms , 2021, Computational and Structural Biotechnology Journal.

[98]  E. Klein,et al.  Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality , 2021, EClinicalMedicine.

[99]  W. Gong,et al.  Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines? , 2021, Journal of Korean medical science.

[100]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[101]  P. Ish,et al.  The initial experience of COVID-19 vaccination from a tertiary care centre of India. , 2021, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[102]  Cynthia Liu,et al.  A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development , 2021, ACS central science.

[103]  Graham W. Taylor,et al.  Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.

[104]  Kathy Katella.  Comparing the COVID-19 Vaccines : How Are They Different ? , 2021, Dental News.

[105]  Yvette N. Lamb.  BNT162b2 mRNA COVID-19 Vaccine: First Approval , 2021, Drugs.

[106]  W. Yin,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2021, Lancet. Infectious Diseases (Print).

[107]  Nguyen H. Tran,et al.  Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.

[108]  P. Dormitzer,et al.  Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.

[109]  N. Patel,et al.  SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.

[110]  K. To,et al.  Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic , 2021, Emerging microbes & infections.

[111]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[112]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[113]  A. Kheradmand,et al.  Psychiatric Adverse Drug Reactions and Potential Anti-COVID-19 Drug Interactions with Psychotropic Medications , 2021, Iranian journal of pharmaceutical research : IJPR.

[114]  Kyung Soo Park,et al.  Non-viral COVID-19 vaccine delivery systems , 2020, Advanced Drug Delivery Reviews.

[115]  A. Gorji,et al.  Potential roles of micronutrient deficiency and immune system dysfunction in the coronavirus disease 2019 (COVID-19) pandemic , 2020, Nutrition.

[116]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[117]  R. Kennedy,et al.  SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates , 2020, The Lancet.

[118]  T. Pollak,et al.  Neuropsychiatric complications of covid-19 , 2020, BMJ.

[119]  A. Al-Katib,et al.  Coagulation and anticoagulation in COVID-19 , 2020, Blood Reviews.

[120]  S. Mohammadi-Samani,et al.  COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection , 2020, Heart & Lung.

[121]  Yongli Yang,et al.  Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. , 2020, JAMA.

[122]  K. Kalantar-Zadeh,et al.  Pharmaco-Immunomodulatory Therapy in COVID-19 , 2020, Drugs.

[123]  I. Abdullahi,et al.  Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions , 2020, Journal of Taibah University Medical Sciences.

[124]  A. Terrinoni,et al.  The COVID-19 pandemic , 2020, Critical reviews in clinical laboratory sciences.

[125]  J. Laukkanen,et al.  Renal complications in COVID-19: a systematic review and meta-analysis , 2020, Annals of medicine.

[126]  Anis Abobaker.  Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome? , 2020, European Journal of Clinical Pharmacology.

[127]  P. Gibson,et al.  COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS , 2020, The Medical journal of Australia.

[128]  G. Gao,et al.  Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.

[129]  A. Qureshi,et al.  Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review , 2020, Therapeutics and clinical risk management.

[130]  E. Shamsoddin.  A COVID-19 pandemic guideline in evidence-based medicine , 2020, Evidence-Based Dentistry.

[131]  S. Mohammadi-Samani,et al.  Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19? , 2020 .

[132]  G. Keser,et al.  Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment , 2020, Clinical Rheumatology.

[133]  B. Long,et al.  Neurologic complications of COVID-19 , 2020, The American Journal of Emergency Medicine.

[134]  C. Mantzoros,et al.  Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens? , 2020, Metabolism.

[135]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[136]  M. Mazer-Amirshahi,et al.  Pharmacotherapy in COVID-19; A narrative review for emergency providers , 2020, The American Journal of Emergency Medicine.

[137]  Theodora Psaltopoulou,et al.  Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.

[138]  S. Hantoushzadeh,et al.  Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with (COVID-19) , 2020, Archives of Medical Research.

[139]  S. Hantoushzadeh,et al.  Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus-19 Disease (COVID-19) , 2020, Archives of Medical Research.

[140]  Larry J. Anderson,et al.  Morbidity and Mortality Weekly Report , 2002 .

[141]  ScienceDirect,et al.  Author's response to letter: Can on-admission anemia predict severe COVID-19 cases? A discussion about statistical and clinical significance , 2021, The American Journal of Emergency Medicine.